2016
New Strategies in Breast Cancer: Immunotherapy
Pusztai L, Karn T, Safonov A, Abu-Khalaf MM, Bianchini G. New Strategies in Breast Cancer: Immunotherapy. Clinical Cancer Research 2016, 22: 2105-2110. PMID: 26867935, PMCID: PMC9359478, DOI: 10.1158/1078-0432.ccr-15-1315.Peer-Reviewed Original ResearchConceptsBreast cancerClinical trialsEffective immune checkpoint inhibitorsObjective tumor response rateEstrogen receptor-positive cancersLocal antitumor immune responsePhase I clinical trialImmune checkpoint inhibitorsTumor response rateAntitumor immune responseReceptor-positive cancersTriple-negative cancersLocal immune microenvironmentHER2-positive cancersMost breast cancersNew treatment modalitiesCheckpoint inhibitorsDurable responsesL1 antibodyLymphocytic infiltrationImmune microenvironmentImmune infiltrationTreatment modalitiesImmune responsePreclinical studies
2012
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers
Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, Holmes FA, O’Shaughnessy J, Hellerstedt B, Pippen J, Vidaurre T, Gomez H, Valero V, Hortobagyi GN, Symmans WF, Bottai G, Di Leo A, Gonzalez-Angulo AM, Pusztai L. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Research And Treatment 2012, 134: 333-343. PMID: 22538770, PMCID: PMC3885980, DOI: 10.1007/s10549-012-2035-3.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBreast cancer subtypesBreast cancerPIK3CA mutationsCancer subtypesEstrogen receptor-positive cancersBreast cancer molecular subtypesMajor breast cancer subtypesSingle needle biopsyProspective clinical trialsReceptor-positive cancersDifferent breast cancer subtypesDifferent clinical subtypesNegative breast cancerCancer molecular subtypesFine-needle aspirationMutation patternsClinical subtypesClinical trialsNeedle biopsyMolecular subtypesNeedle aspirationInvestigational drugsStage IFBXW7 mutationsEstrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry
Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry. Journal Of Clinical Oncology 2012, 30: 729-734. PMID: 22291085, DOI: 10.1200/jco.2011.36.2574.Peer-Reviewed Original ResearchConceptsER-positive patientsIHC-positive patientsER-positive cancersESR1 mRNA expressionGene signature scoreER statusBreast cancerSignature scoreEstrogen receptor-positive cancersMRNA expressionAdjuvant endocrine therapyEndocrine-sensitive tumorsER-negative cohortER-positive cohortER-negative groupER-positive tumorsOverall survival ratePrimary breast cancerER-negative cancersReceptor-positive cancersSafe clinical approachEstrogen receptor mRNAEndocrine therapyER-positiveAffymetrix U133A gene chips
2011
P3-17-01: ApoE and Its Receptors (LRP8, VLDLR) Function as Growth Signals for Triple-Negative Breast Cancer and Represent a Novel Therapeutic Target.
Shiang C, Qi Y, Wang B, Broom B, Pusztai L. P3-17-01: ApoE and Its Receptors (LRP8, VLDLR) Function as Growth Signals for Triple-Negative Breast Cancer and Represent a Novel Therapeutic Target. Cancer Research 2011, 71: p3-17-01-p3-17-01. DOI: 10.1158/0008-5472.sabcs11-p3-17-01.Peer-Reviewed Original ResearchTriple-negative breast cancerER-negative cellsBreast cancerHuman epidermal growth factor 2 receptorReceptor systemAbstract Triple-negative breast cancerStimulatory effectCell linesEarly-onset breast cancerHuman triple-negative breast cancerER-negative cell linesExpression of estrogenReceptor-positive cancersER-positive cellsOnset breast cancerNovel therapeutic targetBreast cancer cell linesBreast cancer tissuesInflammatory signaling pathwaysMAPK/ERK pathwayPreferential growth inhibitionApoE4 expressionCancer cell linesTreatment optionsGrowth factor 2 receptor
2010
Estrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and Metastasis
Pusztai L, Viale G, Kelly CM, Hudis CA. Estrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and Metastasis. The Oncologist 2010, 15: 1164-1168. PMID: 21041379, PMCID: PMC3227913, DOI: 10.1634/theoncologist.2010-0059.Peer-Reviewed Original ResearchConceptsReceptors resultsBreast cancerHuman epidermal growth factor receptor 2 receptor statusRepeat tumor biopsiesRoutine repeat biopsyPrimary breast cancerReceptor-positive cancersReceptor-negative cancersEndocrine therapyFalse-negative resultsReceptor discordanceMetastatic diseaseReceptor statusRepeat biopsyClinical courseRecurrent cancerClinical groundsPrimary tumorTumor nestsEstrogen receptorTumor biopsiesHormone responsivenessReceptor assayCancerDiscordant resultsUse of mutation profiling of breast cancer using sequenom technology to detect distinct mutation patterns in triple-negative compared to receptor-positive cancers.
Santarpia L, Gonzalez-Angulo A, Qi Y, Stemke-Hale K, Wang B, Booser D, Hortobagyi G, Symmans W, Di Leo A, Pusztai L. Use of mutation profiling of breast cancer using sequenom technology to detect distinct mutation patterns in triple-negative compared to receptor-positive cancers. Journal Of Clinical Oncology 2010, 28: 1039-1039. DOI: 10.1200/jco.2010.28.15_suppl.1039.Peer-Reviewed Original ResearchReceptor-positive cancersBreast cancerMutation profilingDistinct mutation patternsMutation patternsCancerSequenom technology
2009
Targeting of breast cancer with non-oncology drugs – possible novel therapeutic option for triple-negative breast cancer.
Liedtke C, Yan K, Wu Y, Hortobagyi G, Symmans W, Valero V, Goette M, Kiesel L, Pusztai L. Targeting of breast cancer with non-oncology drugs – possible novel therapeutic option for triple-negative breast cancer. Cancer Research 2009, 69: 2119. DOI: 10.1158/0008-5472.sabcs-2119.Peer-Reviewed Original ResearchTriple-negative breast cancerBreast cancerTherapeutic optionsCell linesEarly-stage breast cancerHuman triple-negative breast cancerCurrent chemotherapy agentsDrug targetsReceptor-positive cancersStage breast cancerBreast cancer cell line MCF-7Future therapeutic optionsNovel therapeutic optionsCancer cell line MCF-7TNBC cell linesBreast cancer cell linesGlutathione S-transferase piFine-needle biopsyDose-dependent inhibitionLack of ERCell line MCF-7Normal HER2 expressionCancer cell linesUnique drug targetsBiological presentation
2008
An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer. Cancer Research 2008, 68: 6084-6091. PMID: 18676830, PMCID: PMC2680495, DOI: 10.1158/0008-5472.can-07-6854.Peer-Reviewed Original ResearchConceptsPIK3CA mutationsBreast cancerAKT1 mutationsPTEN lossPathway aberrationsHormone receptor-positive breast cancer patientsHormone receptor-positive breast cancerPTEN mutationsReceptor-positive breast cancer patientsHormone receptor-positive cancersPI3K pathway aberrationsCell linesReceptor-positive breast cancerAdjuvant tamoxifen therapyReceptor-positive cancersBreast cancer patientsDifferent breast cancer subtypesDownstream PI3K/AktBasal-like tumorsBreast cancer subtypesHuman breast cancerPI3K inhibitor LY294002PI3K/AktK inhibitor LY294002PI3K inhibition
2005
Adjuvant therapy for breast cancer.
Hennessy B, Pusztai L. Adjuvant therapy for breast cancer. Minerva Obstetrics And Gynecology 2005, 57: 305-26. PMID: 16166938.Peer-Reviewed Original ResearchConceptsBreast cancerAromatase inhibitorsAdjuvant chemotherapyAdjuvant therapyHormonal therapyHormone receptor-positive breast cancerLymph node-positive breast cancerHormone receptor-positive cancersNode-positive breast cancerReceptor-positive breast cancerAdjuvant chemotherapy regimensAnthracycline-based regimenChemo-therapeutic treatmentsIncorporation of trastuzumabSingle best treatmentAdjuvant hormonal therapyOverall survival advantageUse of trastuzumabDose of cyclophosphamideLarge randomized studiesSchedule of administrationSubset of patientsReceptor-positive cancersRisk of relapseImportant clinical advance